Skip to main content

Key new drugs help close out 2024

New biologics for breast cancer, hemophilia, and a rare form of heart disease are poised to add competition and choice in these classes.

Welcome to the Fall 2024 Notable New Drugs Report

New treatments target relatively small, hard-to-treat patient populations with big drug spend.

This edition of the report showcases:

  • A first-in-class treatment for both A and B hemophilia which can reduce the frequency of bleeding episodes.
  • A new addition to standard breast cancer therapy with improved outcomes for people with HR-positive breast cancer.
  • A new drug to treat a rare congenital heart disease can reduce the risk of death by 57%.

Don't want to read the full report? Download the summary.

Related healthcare insights

View all

Guide

Winter: First big drugs of 2024

New treatments for NASH, schizophrenia and more are on the way.

Article

Regulations to watch: Spring 2024

Get the latest on legislation impacting PBM operations.

Article

The new drugs plan sponsors need to watch for

See which trends to consider when assessing the pharmacy benefit, which new drugs may be flying under the radar and what's coming.